DOCSLIB.ORG

National Master List of Drugs and Lab Reagents

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

ITEM NAME 1 CARDIOVASCULAR SYSTEM 1A Positive inotropic drugs 1AA Digtalis glycoside 02-01-00001 Digoxin 62.5mcg Tablet 2539500 02-01-00002 Digitoxin 100mcg Tablet 2397000 02-01-00003 Digoxin 125 mcg Tablet 2622000 02-01-00004 Digoxin 250 mcg Tablet 44165500 02-01-00005 Digoxin 50mcg /ml PG Elixir 800000 02-01-00006 Digoxin 250 mcg/ml inj (2ml) Ampoule 800000 1AB PHOSPHODIESTERASE INHIBITORS 02-01-00007 Enoximone 5mg/1ml inj (20ml) Ampoule 800000 1B DIURETICS 02-01-00008 Amiloride Hcl 5mg + Hydrochlorthiazide 50mg Tablet 50000000 02-01-00009 Bumetanide 1 mg Tablet 1369000 02-01-00010 Chlorthalidone 50mg Tablet 6360500 02-01-00011 Ethacrynic acid 50mg as sodium salt inj (powder for reconstitution) Vial 800000 02-01-00012 Frusemide 20mg/2ml inj Ampoule 9437000 02-01-00013 Frusemide 10mg/ml,I.V.infusion inj (25ml) Ampoule 800000 02-01-00014 Frusemide 40mg Tablet 78372000 02-01-00015 Frusemide 500mg Scored Tablet 800000 02-01-00016 Frusemide 1mg/1ml Oral solution peadiatric Liquid 800000 02-01-00017 Frusemide 4mg/ml Oral Solution 800000 02-01-00018 Frusemide 8mg/ml oral Solution 800000 02-01-00019 Hydrochlorothiazide 25mg Tablet 3173000 02-01-00020 Hydrochlorothiazide 50mg Tablet 3033500 02-01-00021 Indapamide 2.5mg Tablet 800000 02-01-00022 Indapamide 1.5mg S/R Coated Tablet 800000 02-01-00023 Spironolactone 25mg Tablet 8426000 02-01-00024 Spironolactone 100mg Tablet 5829500 02-01-00025 Xipamide 20mg Tablet 800000 1C BETA-ADRENOCEPTER BLOCKING DRUGS 02-01-00026 Acebutolol 100mg Tablet 800000 02-01-00027 Acebutolol 200mg Tablet 800000 02-01-00028 Atenolol 100mg Tablet 120000000 02-01-00029 Atenolol 50mg Tablet or (scored tab) 48893000 02-01-00030 Atenolol 25mg Tablet 8628500 02-01-00031 Bisoprolol fumarate 5mg Scored Tablet 800000 02-01-00032 Bisoprolol fumarate 10mg Scored Tablet 800000 02-01-00033 Carvedilol 6.25mg Tablet 3279500 02-01-00034 Carvedilol 12.5mg Tablet 2228500 02-01-00035 Carvedilol 25mg Tablet 2650000 02-01-00036 Esmolol Hcl 10mg/ml I.V. infusion (10ml) Vial 800000 02-01-00037 Labetalol inj. 5mg/ml (20ml) Ampoule 800000 02-01-00038 Labetalol 200mg Tablet 800000 02-01-00039 Labetalol 400mg Tablet 800000 02-01-00040 Metoprolol 50mg Tablet 800000 02-01-00041 Metoprolol 200mg (s/r) Tablet 1821000 02-01-00042 Metoprolol tartrate 1mg/1ml I.V. inj (5ml) Ampoule 800000 02-01-00043 Metoprolol tartrate 100mg (CR ), (Zok ) Tablet 1088000 02-01-00044 Metoprolol tartrate 50mg (CR), (Zok) Tablet 1150000 02-01-00045 Metoprolol succinate 190mg corr.Metoprolol tartrate controlled release tab 200mg (Zok) 1130000 02-01-00046 Nadolol 80mg Tablet 1667000 02-01-00047 Oxprenolol Hcl 40mg Tablet 4685000 02-01-00048 Pindolol 5mg Tablet 1175000 02-01-00049 Propranolol Hcl 1mg/ml slow IV inj (1ml) Ampoule 800000 02-01-00050 Propranolol Hcl 10mg Tablet 38418500 02-01-00051 Propranolol Hcl 40mg Tablet (or scored Tablet) 60000000 02-01-00052 Propranolol Hcl 80mg (s/r) Capsule 1846500 02-01-00053 Sotalol 40mg Tablet 800000 02-01-00054 Sotalol 80mg Tablet 800000 1D ANTI-ARRHYTHMIC DRUGS 02-01-00055 Adenosine inj. 3mg/ml (2ml) Vial 800000 02-01-00056 Adenosine inj. 3mg/ml (2ml) amp 800000 02-01-00057 Amiodarone Hcl inj 50mg/ml (3ml) Ampoule 800000 02-01-00058 Amiodarone Hcl 200mg Tablet 18347500 02-01-00059 Bretylium tosylate inj 50mg/ml,( 10ml) Ampoule 800000 02-01-00060 Disopyramide 100mg Capsule 2944000 02-01-00061 Disopyramide 150mg (s/r) durules Tablet 800000 02-01-00062 Disopyramide 250mg retard (s/r) Tablet 1277000 02-01-00063 Disopyramide inj 10mg/ml, (5ml) Ampoule 800000 02-01-00064 Lidocaine Hcl 20mg/ml slow I.V. infusion ,(50ml Vial) plain 800000 02-01-00065 Lidocaine Hcl 5% + Dextrose 7.5 % (hyperbaric sol - spinal anesthesia) Injection 800000 02-01-00066 Lidocaine Hcl 1.5% + Dextrose 7.5 % (hyperbaric sol - spinal anesthesia) Injection 800000 02-01-00067 Mexiletine Hcl 50mg Capsule 2499000 02-01-00068 Mexiletine Hcl 200mg Capsule 3713000 02-01-00069 Mexiletine Hcl 25mg/ml I.V.inj.I.V.infusion (10ml) Ampoule 800000 02-01-00070 Phenytoin sodium 50mg/ml inj (5ml) Ampoule 800000 02-01-00071 Practolol 2mg/ml, inj. (5ml) Ampoule 800000 02-01-00072 Procainamide Hcl 100mg/ml slow I.V.inj. I.V. infusion (10ml) Vial 800000 02-01-00073 Procainamide Hcl 500mg Tablet 800000 02-01-00074 Procainamide Hcl 750mg (s/r)Tablet 800000 02-01-00075 Propafenon Hcl 150mg Tablet 800000 02-01-00076 Quinidine Bisulfate 250mg (s/r) Durules equivalent to Quinidine Sulphate 200mg Tablet 800000 02-01-00077 Quinidine Sulphate 200mgTablet 800000 02-01-00078 Verapamil Hcl inj 2.5mg/ml, (2ml) Ampoule 800000 02-01-00079 Verapamil Hcl 40mg Tablet 3752500 02-01-00080 Verapamil Hcl 80mg Tablet 2583500 02-01-00081 Verapamil Hcl 120mg (s/r) Capsule 800000 02-01-00082 Verapamil Hcl 120mg (s/r) Tablet 800000 1E ANTI-HYPERTENSIVE DRUGS 02-01-00083 Alfuzosin Hcl 2.5mg Tablet 10234500 02-01-00084 Alfuzosin Hcl 5mg (s/r)Tablet 4917000 02-01-00085 Alfuzosin Hcl (prolong release) 10mg Tablet 1606500 02-01-00086 Captopril 25mg Tablet 120000000 02-01-00087 Captopril 50mg Tablet 60000000 02-01-00088 Captopril 12.5mg Tablet 908000 02-01-00089 Candesartan cilexetil 8mg Scored Tablet 800000 02-01-00090 Candesartan cilexetil 16mg Tablet 800000 02-01-00091 Diazoxide 50mg Tablet 800000 02-01-00092 Doxazosin mesylate equivalent to doxazosin 2mg Scored Tablet 3507000 02-01-00093 Doxazosin as mesylate 1mg Tablet 800000 02-01-00094 Doxazosin as mesylate 4mg Tablet 800000 02-01-00095 Enalapril maleate 5mg Scored Tablet 5027500 02-01-00096 Enalapril maleate 10mg Scored Tablet 7836000 02-01-00097 Enalapril maleate 20mg Scored Tablet 7916500 02-01-00098 Hydralazine Hcl 20mg I.V. Infusion per Ampoule 800000 02-01-00099 Hydralazine Hcl 25mg Tablet 1539500 02-01-00100 Hydralazine Hcl 50mg Tablet 899000 02-01-00101 Irbesartan 150mg Tablet 885000 02-01-00102 Irbesartan 300mg Tablet 984500 02-01-00103 Lisinopril as dihydrate 5mg Tablet 3487500 02-01-00104 Lisinopril as dihydrate 10mg Tablet 6366500 02-01-00105 Lisinopril as dihydrate 20mg Tablet 6552000 02-01-00106 Losartan potassium 50mg Tablet 870500 02-01-00107 Losartan potassium 25mg Tablet 1206000 02-01-00108 Methyldopa 50mg/ml,inj. (5ml) Ampoule 800000 02-01-00109 Methyldopa 250mgTablet 70000000 02-01-00110 Minoxidil 5mgTablet 800000 02-01-00111 Minoxidil 10mgTablet 800000 02-01-00112 Perindopril tert- butylamine erbumine 2mg Tablet 800000 02-01-00113 Perindopril tert- butylamine erbumine 4mg Tablet 800000 02-01-00114 Phenoxybenzamine Hcl 10mg Capsule 1019500 02-01-00115 Phenoxybenzamine Hcl inj 50mg/ml, (2ml) Ampoule 800000 02-01-00116 Phentolamine mesylate 10mg/ml, (1ml) Ampoule 800000 02-01-00117 Prazosin Hcl 0.5mg Tablet 800000 02-01-00118 Prazosin Hcl 1mg Tablet or Scored Tablet 4830000 02-01-00119 Prazosin Hcl 2mg Tablet 2303500 02-01-00120 Prazosin Hcl 5mg Tablet 2333500 02-01-00121 Quinapril Hcl 5mg Tablet 800000 02-01-00122 Quinapril Hcl 10mg Tablet 800000 02-01-00123 Quinapril Hcl 20mg Tablet 800000 02-01-00124 Ramipril 2.5mg Capsule 800000 02-01-00125 Ramipril 2.5mg Scored Tablet 800000 02-01-00126 Ramipril 5mg Capsule 800000 02-01-00127 Ramipril 5mg Scored Tablet 800000 02-01-00128 Ramipril 10mg Capsule 800000 02-01-00129 Ramipril 10mg Scored Tablet 800000 02-01-00130 Ramipril 1.25mg Capsule 800000 02-01-00131 Reserpine 100mcg Tablet 800000 02-01-00132 Sodium nitroprusside infusion 30mg Ampoule with solvent 800000 02-01-00133 Sodium nitroprusside 50mg I.V. infusion Vial with solvent 800000 02-01-00134 Sodium nitroprusside 50mg I.V. infusion Ampoule with solvent 800000 02-01-00135 Tolazoline Hcl I.V. Injection 800000 02-01-00136 Telmisartan 40mg Tablet 1274500 02-01-00137 Telmisartan 80mg Tablet 1283000 02-01-00138 Valsartan 160mg Capsule 32134500 02-01-00139 Valsartan 40mg Capsule 4263500 02-01-00140 Valsartan 80mg Capsule 50000000 02-01-00141 Valsartan 80mg+hydrochlorthiazide 12.5mg Capsule 5233500 02-01-00142 Valsartan 80mg+hydrochlorthiazide 12.5mg Tablet 5233500 02-01-00143 Valsartan 160mg+hydrochlorthiazide 12.5mg Capsule 3841500 02-01-00144 Valsartan 160mg+hydrochlorthiazide 12.5mg Tablet 3841500 1F VASODILATORS 02-01-00145 Amlodipine (as besylate) 2.5mg Tablet 7239500 02-01-00146 Amlodipine (as besylate) 5mg Scored Tablet 9784500 02-01-00147 Amlodipine (as besylate) 10mg Scored Tablet 3905000 02-01-00148 Amlodipine (as besylate) cap 5mg 800000 02-01-00149 Cinnarizine 25mg Tablet 28404500 02-01-00150 Cinnarizine 75mg Capsule 9191500 02-01-00151 Cinnarizine 75mg Tablet 9191500 02-01-00152 Diltiazem Hcl 60mg Capsule 8251500 02-01-00153 Diltiazem Hcl 60mg Tablet 8251500 02-01-00154 Diltiazem Hcl 90mg (s/r) Capsule 4774000 02-01-00155 Diltiazem Hcl 90mg (s/r) Tablet 4774000 02-01-00156 Diltiazem Hcl 120mg (s/r) Capsule 3044500 02-01-00157 Diltiazem Hcl 120mg (s/r) Tablet 3044500 02-01-00158 Diltiazem Hcl 180mg (s/r) Capsule 800000 02-01-00159 Diltiazem Hcl 180mg (s/r) Tablet 800000 02-01-00160 Diltiazem Hcl 200mg (s/r) Capsule 800000 02-01-00161 Diltiazem Hcl 200mg (s/r) Tablet 800000 02-01-00162 Diltiazem Hcl 240mg (s/r) Capsule 800000 02-01-00163 Diltiazem Hcl 240mg (s/r) Tablet 800000 02-01-00164 Diltiazem Hcl 300mg (s/r) Capsule 800000 02-01-00165 Diltiazem Hcl 300mg (s/r)Tablet 800000 02-01-00166 Diltiazem Hcl 25mg I.V.Infusion Vial 800000 02-01-00167 Diltiazem Hcl 25mg I.V.Inj Vial 800000 02-01-00168 Felodipine 5mg Tablet 1302500 02-01-00169 Glyceryl trinitrate 0.5mg Tablet 60000000 02-01-00170 Glyceryl trinitrate 5mg/10ml Ampoule 800000 02-01-00171 Glyceryl trinitrate 5mg Plaster 1033500 02-01-00172 Glyceryl trinitrate 10mg Plaster 978000 02-01-00173 Glyceryl trinitrate 15mg Plaster 800000 02-01-00174 Glyceryl trinitrate
Recommended publications
  • The National Drugs List

    The National Drugs List

    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
  • Anthem Blue Cross Drug Formulary

    Anthem Blue Cross Drug Formulary

    Erythromycin/Sulfisoxazole (generic) INTRODUCTION Penicillins ...................................................................... Anthem Blue Cross uses a formulary Amoxicillin (generic) (preferred list of drugs) to help your doctor Amoxicillin/Clavulanate (generic/Augmentin make prescribing decisions. This list of drugs chew/XR) is updated quarterly, by a committee Ampicillin (generic) consisting of doctors and pharmacists, so that Dicloxacillin (generic) the list includes drugs that are safe and Penicillin (generic) effective in the treatment of diseases. If you Quinolones ..................................................................... have any questions about the accessibility of Ciprofloxacin/XR (generic) your medication, please call the phone number Levofloxacin (Levaquin) listed on the back of your Anthem Blue Cross Sulfonamides ................................................................ member identification card. Erythromycin/Sulfisoxazole (generic) In most cases, if your physician has Sulfamethoxazole/Trimethoprim (generic) determined that it is medically necessary for Sulfisoxazole (generic) you to receive a brand name drug or a drug Tetracyclines .................................................................. that is not on our list, your physician may Doxycycline hyclate (generic) indicate “Dispense as Written” or “Do Not Minocycline (generic) Substitute” on your prescription to ensure Tetracycline (generic) access to the medication through our network ANTIFUNGAL AGENTS (ORAL) _________________ of community
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
  • The In¯Uence of Medication on Erectile Function

    The In¯Uence of Medication on Erectile Function

    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
  • Anticholinergic Drugs Improve Symptoms but Increase Dry Mouth in Adults with Overactive Bladder Syndrome

    Anticholinergic Drugs Improve Symptoms but Increase Dry Mouth in Adults with Overactive Bladder Syndrome

    Source of funding: Evid Based Nurs: first published as 10.1136/ebn.6.2.49 on 1 April 2003. Downloaded from Review: anticholinergic drugs improve symptoms but Health Research Council of Aotearoa increase dry mouth in adults with overactive bladder New Zealand. syndrome For correspondence: Jean Hay-Smith, Hay-Smith J, Herbison P,Ellis G, et al. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Dunedin School of Cochrane Database Syst Rev 2002;(3):CD003781 (latest version May 29 2002). Medicine, University of Otago, Dunedin, New QUESTION: What are the effects of anticholinergic drugs in adults with overactive Zealand. jean.hay-smith@ bladder syndrome? otago.ac.nz Data sources Parallel arm studies of anticholinergic drugs v placebo for overactive bladder syndrome in Studies were identified by searching the Cochrane adults at 12 days to 12 weeks* Incontinence Group trials register (to January 2002) Weighted event rates and reference lists of relevant papers. Anticholinergic Study selection Outcomes drugs Placebo RBI (95% CI) NNT (CI) Randomised or quasi-randomised controlled trials in Self reported cure or adults with symptomatic diagnosis of overactive bladder improvement (8 studies) 63% 45% 41% (29 to 54) 6 (5 to 8) syndrome, urodynamic diagnosis of detrusor overactiv- RRI (CI) NNH (CI) ity, or both, that compared an anticholinergic drug Dry mouth (20 studies) 36% 15% 138 (70 to 232) 5 (4 to 7) (given to decrease symptoms of overactive bladder) with Outcomes Weighted mean difference (CI) placebo or no treatment. Studies of darifenacin, emepronium bromide or carrageenate, dicyclomine Number of leakage episodes in 24 hours (9 − chloride, oxybutynin chloride, propiverine, propanthe- studies) 0.56 (–0.73 to –0.39) Number of micturitions in 24 hours (8 studies) −0.59 (–0.83 to –0.36) line bromide, tolterodine, and trospium chloride were Maximum cystometric volume (ml) (12 studies) 54.3 (43.0 to 65.7) included.
  • Model Answer

    Model Answer

    MAHARASHTRA STATE BOARD OF TECHNICAL EDUCATION (Autonomous) (ISO/IEC - 27001 - 2005 Certified) MODEL ANSWER WINTER– 18 EXAMINATION Subject Title: PHARMACEUTICAL CHEMISTRY-l Subject Code: 0806 ________________________________________________________________________________________ Important Instructions to examiners: 1) The answers should be examined by key words and not as word-to-word as given in the model answer scheme. 2) The model answer and the answer written by candidate may vary but the examiner may try to assess the understanding level of the candidate. 3) The language errors such as grammatical, spelling errors should not be given more Importance (Not applicable for subject English and Communication Skills. 4) While assessing figures, examiner may give credit for principal components indicated in the figure. The figures drawn by candidate and model answer may vary. The examiner may give credit for anyequivalent figure drawn. 5) Credits may be given step wise for numerical problems. In some cases, the assumed constant values may vary and there may be some difference in the candidate’s answers and model answer. 6) In case of some questions credit may be given by judgement on part of examiner of relevant answer based on candidate’s understanding. 7) For programming language papers, credit may be given to any other program based on equivalent concept. Page no.1/28 MAHARASHTRA STATE BOARD OF TECHNICAL EDUCATION (Autonomous) (ISO/IEC - 27001 - 2005 Certified) MODEL ANSWER WINTER– 18 EXAMINATION Subject Title: PHARMACEUTICAL CHEMISTRY-l Subject Code: 0806 ________________________________________________________________________________________ 1 ANSWER ANY EIGHT OF THE FOLLOWING. 16M (8x2) 1 a) State any four ideal properties of buffer solution. ANY The pH of buffer solution remains constant.
  • Influence of Bowel Preparation Before 18F-FDG PET/CT on Physiologic

    Influence of Bowel Preparation Before 18F-FDG PET/CT on Physiologic

    Influence of Bowel Preparation Before 18F-FDG PET/CT on Physiologic 18F-FDG Activity in the Intestine Jan D. Soyka1, Klaus Strobel1, Patrick Veit-Haibach1, Niklaus G. Schaefer1, Daniel T. Schmid1, Alois Tschopp2, and Thomas F. Hany1 1Department of Nuclear Medicine, University Hospital, Zurich, Switzerland; and 2Department for Biostatistics, University of Zurich, Zurich, Switzerland Our objective was to investigate the use of bowel preparation be- mendations have been made in order to reduce physiologic fore 18F-FDG PET/CT to reduce intestinal 18F-FDG uptake. uptake of 18F-FDG in the intestine or to improve the ability Methods: Sixty-five patients with abdominal neoplasias were to evaluate intestinal structures (5–8). However, no published assigned either to a bowel-preparation group (n 5 26) or to a na- tive group (n 5 39). 18F-FDG activity was measured in the small study has proven that bowel preparation before PET/CT intestine and the colon. Results: In the 26 patients with bowel is beneficial. We therefore conducted a naturally randomized preparation, average maximal standardized uptake value (SUV- and single-blinded study to evaluate the effects of bowel max) was 3.5 in the small intestine and 4.4 in the colon. In the cleansing on intestinal 18F-FDGactivityinPET/CT. 39 patients without bowel preparation, average SUVmax was 2.6 in the small intestine and 2.7 in the colon. 18F-FDG activity im- MATERIALS AND METHODS paired diagnosis in 6 patients (23%) in the bowel-preparation group and 11 patients (28%) in the native group (P 5 0.5). SUV- This prospective, naturally randomized, and single-blinded max in the colon was significantly higher in the bowel-prepara- study was approved by our local ethics committee.
  • Zebrafish Behavioral Profiling Links Drugs to Biological Targets and Rest/Wake Regulation

    Zebrafish Behavioral Profiling Links Drugs to Biological Targets and Rest/Wake Regulation

    www.sciencemag.org/cgi/content/full/327/5963/348/DC1 Supporting Online Material for Zebrafish Behavioral Profiling Links Drugs to Biological Targets and Rest/Wake Regulation Jason Rihel,* David A. Prober, Anthony Arvanites, Kelvin Lam, Steven Zimmerman, Sumin Jang, Stephen J. Haggarty, David Kokel, Lee L. Rubin, Randall T. Peterson, Alexander F. Schier* *To whom correspondence should be addressed. E-mail: [email protected] (A.F.S.); [email protected] (J.R.) Published 15 January 2010, Science 327, 348 (2010) DOI: 10.1126/science.1183090 This PDF file includes: Materials and Methods SOM Text Figs. S1 to S18 Table S1 References Supporting Online Material Table of Contents Materials and Methods, pages 2-4 Supplemental Text 1-7, pages 5-10 Text 1. Psychotropic Drug Discovery, page 5 Text 2. Dose, pages 5-6 Text 3. Therapeutic Classes of Drugs Induce Correlated Behaviors, page 6 Text 4. Polypharmacology, pages 6-7 Text 5. Pharmacological Conservation, pages 7-9 Text 6. Non-overlapping Regulation of Rest/Wake States, page 9 Text 7. High Throughput Behavioral Screening in Practice, page 10 Supplemental Figure Legends, pages 11-14 Figure S1. Expanded hierarchical clustering analysis, pages 15-18 Figure S2. Hierarchical and k-means clustering yield similar cluster architectures, page 19 Figure S3. Expanded k-means clustergram, pages 20-23 Figure S4. Behavioral fingerprints are stable across a range of doses, page 24 Figure S5. Compounds that share biological targets have highly correlated behavioral fingerprints, page 25 Figure S6. Examples of compounds that share biological targets and/or structural similarity that give similar behavioral profiles, page 26 Figure S7.
  • Drug Consumption in 2017 - 2020

    Drug Consumption in 2017 - 2020

    Page 1 Drug consumption in 2017 - 2020 2020 2019 2018 2017 DDD/ DDD/ DDD/ DDD/ 1000 inhab./ Hospital 1000 inhab./ Hospital 1000 inhab./ Hospital 1000 inhab./ Hospital ATC code Subgroup or chemical substance day % day % day % day % A ALIMENTARY TRACT AND METABOLISM 322,79 3 312,53 4 303,08 4 298,95 4 A01 STOMATOLOGICAL PREPARATIONS 14,28 4 12,82 4 10,77 6 10,46 7 A01A STOMATOLOGICAL PREPARATIONS 14,28 4 12,82 4 10,77 6 10,46 7 A01AA Caries prophylactic agents 11,90 3 10,48 4 8,42 5 8,45 7 A01AA01 sodium fluoride 11,90 3 10,48 4 8,42 5 8,45 7 A01AA03 olaflur 0,00 - 0,00 - 0,00 - 0,00 - A01AB Antiinfectives for local oral treatment 2,36 8 2,31 7 2,31 7 2,02 7 A01AB03 chlorhexidine 2,02 6 2,10 7 2,09 7 1,78 7 A01AB11 various 0,33 21 0,21 0 0,22 0 0,24 0 A01AD Other agents for local oral treatment 0,02 0 0,03 0 0,04 0 - - A01AD02 benzydamine 0,02 0 0,03 0 0,04 0 - - A02 DRUGS FOR ACID RELATED DISORDERS 73,05 3 71,13 3 69,32 3 68,35 3 A02A ANTACIDS 2,23 1 2,22 1 2,20 1 2,30 1 A02AA Magnesium compounds 0,07 22 0,07 22 0,08 22 0,10 19 A02AA04 magnesium hydroxide 0,07 22 0,07 22 0,08 22 0,10 19 A02AD Combinations and complexes of aluminium, 2,17 0 2,15 0 2,12 0 2,20 0 calcium and magnesium compounds A02AD01 ordinary salt combinations 2,17 0 2,15 0 2,12 0 2,20 0 A02B DRUGS FOR PEPTIC ULCER AND 70,82 3 68,91 3 67,12 3 66,05 4 GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 0,17 7 0,74 4 1,10 4 1,11 5 A02BA02 ranitidine 0,00 1 0,63 3 0,99 3 0,99 4 A02BA03 famotidine 0,16 7 0,11 8 0,11 10 0,12 9 A02BB Prostaglandins 0,04 62
  • NINDS Custom Collection II

    NINDS Custom Collection II

    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
  • Histamine Receptors

    Histamine Receptors

    Tocris Scientific Review Series Tocri-lu-2945 Histamine Receptors Iwan de Esch and Rob Leurs Introduction Leiden/Amsterdam Center for Drug Research (LACDR), Division Histamine is one of the aminergic neurotransmitters and plays of Medicinal Chemistry, Faculty of Sciences, Vrije Universiteit an important role in the regulation of several (patho)physiological Amsterdam, De Boelelaan 1083, 1081 HV, Amsterdam, The processes. In the mammalian brain histamine is synthesised in Netherlands restricted populations of neurons that are located in the tuberomammillary nucleus of the posterior hypothalamus.1 Dr. Iwan de Esch is an assistant professor and Prof. Rob Leurs is These neurons project diffusely to most cerebral areas and have full professor and head of the Division of Medicinal Chemistry of been implicated in several brain functions (e.g. sleep/ the Leiden/Amsterdam Center of Drug Research (LACDR), VU wakefulness, hormonal secretion, cardiovascular control, University Amsterdam, The Netherlands. Since the seventies, thermoregulation, food intake, and memory formation).2 In histamine receptor research has been one of the traditional peripheral tissues, histamine is stored in mast cells, eosinophils, themes of the division. Molecular understanding of ligand- basophils, enterochromaffin cells and probably also in some receptor interaction is obtained by combining pharmacology specific neurons. Mast cell histamine plays an important role in (signal transduction, proliferation), molecular biology, receptor the pathogenesis of various allergic conditions. After mast cell modelling and the synthesis and identification of new ligands. degranulation, release of histamine leads to various well-known symptoms of allergic conditions in the skin and the airway system. In 1937, Bovet and Staub discovered compounds that antagonise the effect of histamine on these allergic reactions.3 Ever since, there has been intense research devoted towards finding novel ligands with (anti-) histaminergic activity.
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.